Paul Alexander

Cooley advised Eagle Pharmaceuticals, a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise, on its cooperation agreement with Nantahala Capital Management, a holder of approximately 38% of Eagle’s outstanding shares.

Cooley advised Packable, the holding company for technology-led ecommerce marketplace enablement platform Pharmapacks, on its definitive agreement to merge with special purpose acquisition company (SPAC) Highland Transcend Partners I Corp. Partners Sacha Ross, David Silverman, Nicolas Dumont and Stephanie Gentile led the Cooley team advising Packable.

Cooley advised MaxCyte on its $201.8 million initial public offering of 15,525,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. MaxCyte, whose securities now trade on the Nasdaq Global Select Market under the symbol “MXCT,” also trades on the London Stock Exchange under the symbols "MXCT" and "MXCN." MaxCyte is a leading provider of cell-engineering platform technologies. Partners Christian Plaza, Brian Leaf and Claire Keast-Butler led the Cooley team.